Tchaikapharma High Quality Medicines and the academic community join efforts for the improvement of life expectancy and quality.
We have created a novel model of cooperation between academia and business. In addition to the discussions held at annual scientific congresses, we have established a long-term framework of regular meetings with leading European and American experts, allowing for less adversarial dialogue.
All meetings and activities follow the strict agenda set by the most pressing issues in each field of medicine – poor disease control, inadequate adherence to guidelines in everyday practice, implementation of new diagnostic or treatment algorithms, introduction of new molecules, latest advances from the world scientific events, our own epidemiological studies design and more.
Our healthcare modernization strategy involves regular regional meetings and seminars with physicians from outpatient and inpatient care, moderated by members of our advisory board. Along with the problems, the main discussion is focused on the solutions: better diagnostics, referral, treatment and outcomes. Academic leaders share updated information regarding disease control and patient segmentation in the respective region for various therapeutic fields.
These discussions and debates help us prepare an improved action plan with better problem targeting and involvement of all parties concerned – GPs, specialists, ER, hospitals, regulators. Agenda update and action plan implementation are entrusted to the regional leaders and the members of the advisory boards. All advisory boards are regularly consulted and guided by leading EU and US experts as part of the international activities of Tchaikapharma High Quality Medicines.
In cooperation with the Bulgarian Cardiac Institute, Tchaikapharma has decreased in-hospital mortality from acute coronary syndrome (ACS) in the entire region of Pleven by 30% in just one year. The agenda of all regional meetings organized by Tchaikapharma High Quality Medicines during this period was designed so as to promote not only affordable medical treatment, but also diagnostic and treatment algorithms for ACS, superior interventional treatment and discharge therapy guidelines.
“The Bulgarian Cardiac Institute has established a modern cardiac hospital with a cathlab in the Medical University in Pleven and has decreased the AMI mortality by 30% in one year, taking all the necessary steps according to the ESC guidelines”
Source: T Vekov, M Grigorov, V Georgiev, S Djambazov, L Groch, O Hlinomaz, J Sitar, M Rezek. Decrease in acute coronary syndrome mortality in Pleven region. Implementation of scientific evidence into everyday practice. Journal of Biomedical & Clinical Research (JBCR), Medical University Pleven, 2008, volume 1, number 1, 56 – 61
Tchaikapharma High Quality Medicines has operating Advisory Boards in various specialized fields, including:
Our board members are university professors from all Medical Universities in Bulgaria (Sofia, Plovdiv, Pleven, Stara Zagora, Varna), as well as international experts from the European Union and the USA